2023年7月14日

公司的創新使患者采取精確的血液樣本使用一張特別的卡片,然後發送郵政標準進行分析。總經理邁克爾Barbella Editor07.14.23浩了略高於570萬美元,擴大和商業化self-sampling技術為遠程醫療解決方案和個性化醫療。資金將用於提高生產能力,開發新產品,加大銷售和營銷努力。投資輪由Sciety和網絡Sciety合資企業的合作夥伴。“感謝Sciety的繼續支持,我們能夠加速增長和擴大生產能力。他們在生命科學專業知識結合行業連接將寶貴的浩在我們繼續前進。我們相信,我們的self-sampling技術將成為醫療行業的遊戲規則的改變者,為患者提供更大的便利和可訪問性,同時保證精確的結果,“浩CEO Christopher Aulin說。浩self-sampling技術使患者采取精確的血液樣本使用一張特別的卡片,然後發送分析標準郵政服務不需要製冷或特殊包裝。浩正經曆著不斷增長的需求為其產品在幾個市場和最近與幾個經銷商。浩正努力建立自己self-sampling解決方案的領先供應商的市場領先的臨床準確性。 The company's rapid growth has attracted continued support from Sciety and its network Sciety Venture Partners, which have invested in Capitainer for the third time since 2019. "We are excited to invest in Capitainer again and support their vision of revolutionizing blood sample collection. Capitainer's innovative platform has the potential to significantly impact personalised medicine and remote healthcare, which is perfectly in line with Sciety's vision to bring healthcare breakthroughs to people worldwide," Sciety Managing Partner Andreas Lindblom stated. Capitainer AB is a Swedish medtech company founded in 2016 that develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies. Trending